Login
$SRPT
$15.10 -$0.03 (0.19%) After hours

Company Executives

Officer Age In this role Joined 2025 pay Source
Michael Severino Also a director
Chief Executive Officer
Title from the Form 8-K dated Jul 28, 2026
Not stated Not stated Not stated Not reported
Ryan H. Wong
Executive Vice President, Chief Financial Officer
47 Since 2025
1 year
Not stated $3,211,867
Ian M. Estepan
President, Chief Operating Officer
50 Since 2025
1 year
2015 $4,444,392
Cristin L. Rothfuss
Executive Vice President, General Counsel
58 Since 2024
2 years
2018 $4,233,623
Louise Rodino-Klapac
President, R&D and Tech Ops
Title from the Form 4 dated Sep 4, 2026
48 Not stated 2018 $4,456,270

Each officer opens the passage of the filing that names them. A title that changed since the list comes from the officer's latest Form 3, 4 or 5, and its start year is not stated there. "Not stated" means the filing does not say. Pay is the proxy's Summary Compensation Table, which reports only the named executive officers.

Board of Directors

From the proxy statement filed Apr 24, 2026 · updated by the 8-K of Jul 27, 2026

Directors
10
serving now
Average tenure
8.8 years
from year joined
CEO also chairs the board
No
M. Kathleen Behrens, Ph.D.
Director Age On board Committees Other public boards 2025 pay Source
M. Kathleen Behrens, Ph.D.
73 2009
17 years
Audit Committee · Chair
MiMedx Group Inc. $603,923
Douglas S. Ingram
63 2017
9 years
None stated Relay Therapeutics Paid as CEO
Michael Severino Joined Jul 28, 2026
- - - - Paid as CEO
Hans Wigzell, M.D., Ph.D.
87 2010
16 years
Nominating and Corporate Governance Committee Research and Development Committee · Chair
RaySearch Laboratories AB $562,466
Kathryn J. Boor, Ph.D.
67 2022
4 years
Compensation Committee
Seneca Foods Corporation $552,466
Michael Chambers
51 2022
4 years
Research and Development Committee
Calviri Inc $544,466
Deirdre Connelly
65 2024
2 years
Compensation Committee · Chair Nominating and Corporate Governance Committee
Macy’s Corporation, Lincoln Financial Group, Genmab A/B $558,153
Richard J. Barry
67 2015
11 years
Nominating and Corporate Governance Committee · Chair
Filana Therapeutics, Inc. $577,279
Stephen L. Mayo, Ph.D.
64 2021
5 years
Audit Committee Research and Development Committee
Merck, Allogene Therapeutics $556,966
Claude Nicaise, M.D.
73 2015
11 years
Compensation Committee Research and Development Committee
Minoryx, Gain Therapeutics, Chemomab, Filana Therapeutics, Inc. $554,466

Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive. A director marked Joined was added by an 8-K; their row opens that 8-K, and a dash is a value it does not give.

1 disclosed in the proxy filed Apr 24, 2026
Michael A. Chambers Living Trust
an entity affiliated with Michael Chambers, a member of our Board of Directors
$20.0 million in aggregate principal amount

Privately negotiated exchange of $20.0 million principal of 1.25% Convertible Senior Notes due 2027 for $20.0 million of 4.875% Convertible Senior Notes due 2030 and approximately $2.2 million in cash.

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support